Comparação do custo de formas farmacêuticas sólidas orais para tratamento de osteoartrite / Comparing the cost in oral solid pharmaceutical dosage forms for treatment of osteoarthritis

Carla Tamires Faria, Larissa Marques Pereira, Guilherme Ferreira Menezes, Grazielle Aparecida Silva Maia, Renê Oliveira do Couto, Diego da Silva Ribeiro, Ana Julia Pereira Santinho Gomes

Abstract


A osteoartrite (OA) caracteriza-se pela degradação progressiva da cartilagem articular acompanhada por alterações ósseas subcondrais que levam a restrição de atividades físicas e afetam a qualidade de vida dos pacientes. Os tratamentos disponíveis geralmente são longos e onerosos influenciando na adesão terapêutica e benefícios futuros. Comparou-se o custo mensal de formas farmacêuticas sólidas orais contendo sulfato de glucosamina associado ou não ao sulfato de condroitina, ambas produzidas por farmácias de manipulação situadas no interior de Minas Gerais e por laboratórios farmacêuticos brasileiros. Para tanto, investigou-se o custo do sulfato de glucosamina 1500 mg (G1500) na forma de pó fabricado por sete laboratórios farmacêuticos. Pesquisou-se também o custo da associação de G1500 e sulfato de condroitina 1200 mg (C1200) nas formas de pó e cápsula fabricadas por três laboratórios farmacêuticos. Compararam-se os custos encontrados em relação às respectivas preparações manipuladas (PM). As PM exibiram custos significativamente inferiores em relação aos produtos industrializados. O custo do pó (G1500) manipulado foi 147 % menor que o industrializado. Já os valores encontrados para o pó contendo a associação (G1500 + C1200) foram, em média, 189 % inferiores às especialidades farmacêuticas. Por fim, nas cápsulas contendo a associação (G1500 + C1200), o custo encontrado foi aproximadamente 61 % menor. É evidente que as farmácias de manipulação oferecem o referido tratamento por um valor mais acessível, seja para a associação de G1500 e C1200 ou apenas G1500, independentemente da forma farmacêutica.

 


Keywords


osteoartrite, glucosamine, condroitina, custo.

References


Zhu X, Sang L, Wu D, Rong J, Jian L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13:170. doi: 10.1186/s13018-018-0871-5.

Kim JR, Yoo JJ, ID , Kim HA. Therapeutics in osteoarthritis based on an understanding of its molecular pathogenesis. Int J Mol Sci. 2018;19:674. doi: 10.3390/ijms19030674.

Vasiliadis HS, Tsikopoulos K. Glucosamine and chondroitin for the treatment of osteoarthritis. World J Orthop. 2017;8(1):1-11. doi: 10.5312/wjo.v8.i1.1.

Pacca DM, De-Campos GC, Zorzi AR, Chaim EA, De-Miranda JB. Prevalence of joint pain and osteoarthritis in obese Brazilian population. Arq Bras Cir Dig. 2018;31(1):e1344. doi: 10.1590/0102-672020180001e1344.

Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, Woods RJ, Lieberman DE. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci USA. 2017;114(35):9332-9336. doi: 10.1073/pnas.1703856114.

Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LVB, Ciconelli RM, Ferraz MB. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004;31(3):594-7.

Michael JWP, Schlüter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch Arztebl Int. 2010;107(9):152-62. doi: 10.3238/arztebl.2010.0152.

Seed SM, Dunican KC, Lynch AM. Osteoarthritis: a review of treatment options. Geriatrics. 2009 Oct;64(10):20-9.

Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthr Cartilage. 2019;27(3):359-364. doi: 10.1016/j.joca.2018.11.001.

Bruyère O, Reginster JY, Honvo G, Detilleux J. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res. 2019;31(6):881-7. doi: 10.1007/s40520-019-01138-1.

Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, Al-Daghri NM, Herrero-Beaumont G, Martel-Pelletier J, Pelletier JP, Rannou F, Rizzoli R, Roth R, Uebelhart D, Cooper C, Reginster JY. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. doi: 10.1016/j.semarthrit.2019.04.008.

Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage. 2015;6(1):30-44. doi: 10.1177/1947603514554992.

McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283(11):1469-75. doi: 10.1001/jama.283.11.1469.

Lopes Júnior OV, Inácio AM. Use of glucosamine and chondroitin to treat osteoarthritis: a review of the literature. Rev Bras Ortop. 2013;48(4):300-6. doi: 10.1016/j.rboe.2012.12.001.

Martel-Pelletier J, Farran A, Montell E, Vergés J, Pelletier JP. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015;20(3):4277-89. doi: 10.3390/molecules20034277.

Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P. Meta-analysis: Chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90. doi: 10.7326/0003-4819-146-8-200704170-00009.

Restaino OF, Finamore R, Diana P, Marseglia M, Vitiello M, Casillo A, Bedini E, Parrilli M, Corsaro MM, Trifuoggi M, De Rosa M, Schiraldi C. A multi-analytical approach to better assess the keratan sulfate contamination in animal origin chondroitin sulfate. Anal Chim Acta. 2017;958:59-70. doi: 10.1016/j.aca.2016.12.005.

Santos GRC, Piquet AA, Glauser BF, Tovar AMF, Pereira MS, Vilanova E, Mourão PAS. Systematic analysis of pharmaceutical preparations of chondroitin sulfate combined with glucosamine. Pharmaceuticals (Basel). 2017;10(2):38. doi: 10.3390/ph10020038.

Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi: 10.1056/NEJMoa052771.

Dahmer S, Schiller RM. Glucosamine. Am Fam Physician. 2008;78(4):471-6.

Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G; CS/GS Combined Therapy Study Group. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis. Arthritis Rheumatol. 2017;69(1):77-85. doi: 10.1002/art.39819.

Laba TL, Brien JA, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013;14:160. doi: 10.1186/1471-2474-14-160.

Gindri AL, De Souza LB, Gindri LL, Gindri, AL. Análise dos consumidores de drogarias e farmácias e índice de aceitação dos medicamentos manipulados na cidade de São Francisco de Assis, RS. Rev Bras Farm. 2013;94(2):184-8.

Leal AS, Melo FPS, Gomes TCB, Santana AS, Cunha TH, Saiki M. Preliminary assessment of the quality of the fluoxetine commercialized by pharmacies of manipulation from the city of Belo Horizonte/Brazil. Vigil Sanit Debate 2017;5(1):76-83. doi: 10.22239/2317-269x.00810.

Dumoff A. Food and Drug Administration restrictions on drug compounding: Needed medications are going to disappear: A call for intervention. Integr Med (Encinitas). 2018;17(3):22-8. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396767/pdf/imcj-17-22.pdf

Instituto Brasileiro de Geografia e Estatística - IBGE. Itaúna. Disponível em: https://www.ibge.gov.br/cidades-e-estados/mg/itauna.html.

Maldonado M, Nam J. The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. Biomed Res Int. 2013;2013:284873. doi: 10.1155/2013/284873

Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ, Pelletier JP Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072. doi: 10.1038/nrdp.2016.72.

Cheleschi S, Barbarino M, Gallo I, Tenti S, Bottaro M, Frati E, Giannotti S, Fioravanti A. Hydrostatic pressure regulates oxidative stress through microRNA in human osteoarthritic chondrocytes. Int J Mol Sci. 2020;21(10):3653. https://doi.org/10.3390/ijms21103653.

Ahmada N, Ansarib MY, Bano S, Haqqi TM. Imperatorin suppresses IL-1β-induced iNOS expression via inhibiting ERKMAPK/AP1 signaling in primary human OA chondrocytes. Int Immunopharmacol. 2020;85:106612. https://doi.org/10.1016/j.intimp.2020.106612.

Gourdine J. Review of nonsurgical treatment guidelines for lower extremity osteoarthritis. Orthopaedic Nursing 2019;38(5):303-8. doi: 10.1097/NOR.0000000000000591.

Hermann W, Lambova S, Muller-Ladner U. Current treatment options for osteoarthritis. Curr Rheumatol Rev. 2018;14(2):108-116. doi: 10.2174/1573397113666170829155149.

Bruyère O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4):S12-S17. https://doi.org/10.1016/j.semarthrit.2015.11.011.

Provenza JR, Shinjo SK, Silva JM, Peron CR, Rocha FA. Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol. 2015;34(8):1455-62. doi: 10.1007/s10067-014-2757-1.

Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(4 Suppl):S34-S41. doi: 10.1016/j.semarthrit.2015.10.009.

Saengnipanthkul S, Waikakul S, Rojanasthien S, Totemchokchyakarn K, Srinkapaibulaya A, Chin TC, Hong NM, Bruyère O, Cooper C, Reginster JY, Lwin M. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. Int J Rheum Dis. 2019;22(3):376-85. doi: 10.1111/1756-185X.13068.

Pérez-Ibarbia L, Majdanski T, Schubert S, Windhab N, Schubert US. Safety and regulatory review of dyes commonly used as excipients in pharmaceutical and nutraceutical applications. Eur J Pharm Sci. 2016;93:264-73. doi: 10.1016/j.ejps.2016.08.026.

Benzi JRL, Mastroianni PC. Analysis of extemporaneous oral liquid from commercially available drugs in hospital. Braz J Pharm Sci. 2016;52(3):517-25. https://doi.org/10.1590/s1984-82502016000300017.

Neumann U, Burau D, Spielmann S, Whitaker MJ, Ross RJ, Kloft C, Blankenstein O. Quality of compounded hydrocortisone capsules used in the treatment of children. Eur J Endocrinol. 2017;177(2):239-42. doi: 10.1530/EJE-17-0248.




DOI: https://doi.org/10.34119/bjhrv3n4-071

Refbacks

  • There are currently no refbacks.